Back
Compare AU
Compare JNDQ vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Nasdaq Next Gen 100 ETF (JNDQ) and the S&P US Biotech (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
JNDQ | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 25 | 70 |
Median incremental investment | $574.29 | $673.61 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,160.00 | $1,992.69 |
Average age group | > 35 | > 35 |
Key Summary
JNDQ | CURE | |
|---|---|---|
Strategy | JNDQ.AX was created on 2024-02-20 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. JNDQ.AX aims to track the performance of the Nasdaq Next Generation 100 Index (before fees and expenses). | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | LUMENTUM HOLDINGS INC (3.16 %) TERADYNE INC (2.75 %) FLEX LTD (2.56 %) | TG Therapeutics Inc (1.69 %) Travere Therapeutics Inc Ordinary Shares (1.60 %) Revolution Medicines Inc Ordinary Shares (1.58 %) |
Top 3 industries | Information Technology (31.25 %) Health Care (18.55 %) Other (11.92 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (86.38 %) China (2.75 %) Israel (2.37 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0.48 % | 0.45 % |
Key Summary
JNDQ | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Nasdaq Next Generation 100 Index | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.48 % | 0.45 % |
Price | $19.89 | $63.54 |
Size | N/A | $41.436 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.05 % | 5.08 % |
Market | ASX | ASX |
First listed date | 21/02/2024 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
JNDQ | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 25 | 70 |
Median incremental investment | $574.29 | $673.61 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,160.00 | $1,992.69 |
Average age group | > 35 | > 35 |
Pros and Cons
JNDQ | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
JNDQ | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |